Revenue: The sum of all revenue fields included for a company's operating activities.
Ultragenyx Pharmaceutical Inc. (RARE) had Revenue of $166.50M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
|
Revenue |
$166.50M |
$-114.95M |
|
$23.00M |
|
$143.49M |
|
$274.38M |
|
$-107.89M |
|
$-6.12M |
|
$-114.00M |
|
$-114.00M |
|
$-114.95M |
|
$-114.95M |
|
$-114.95M |
|
$-114.95M |
|
$-107.89M |
|
$-100.32M |
|
98.46M |
|
98.46M |
|
$-1.17 |
|
$-1.17 |
|
| Balance Sheet Financials | |
$719.79M |
|
$255.76M |
|
$586.48M |
|
$1.31B |
|
$293.24M |
|
-- |
|
$861.74M |
|
$1.15B |
|
$151.29M |
|
$-67.85M |
|
$151.29M |
|
96.35M |
|
| Cash Flow Statement Financials | |
$-274.75M |
|
$191.06M |
|
$83.81M |
|
$184.16M |
|
$188.64M |
|
$4.49M |
|
$78.45M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.45 |
|
-- |
|
-- |
|
-- |
|
-- |
|
86.18% |
|
-64.80% |
|
-64.80% |
|
-- |
|
-68.47% |
|
-69.04% |
|
$-278.53M |
|
-- |
|
-- |
|
-- |
|
0.13 |
|
0.49 |
|
1.34 |
|
67.28 |
|
-75.98% |
|
169.41% |
|
-8.80% |
|
-75.98% |
|
$1.57 |
|
$-2.83 |
|
$-2.79 |
|